ClinicalTrials.gg
CompletedNCT05346718UBAMBIUpdated Jul 24, 2026

Threshold Concentrations for Ragweed and Birch Pollen in Seasonal Allergic Rhinitis

An interventional study of Ragweed pollen, birch pollen, clean air (placebo) in Allergic Rhinitis, Seasonal Allergic Rhinitis and Ragweed Allergy, sponsored by Fraunhofer-Institute of Toxicology and Experimental Medicine. Completed at 1 site in Germany. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-24.

Primary conditionRhinitis, Allergic, SeasonalRegistry: Rhinitis, AllergicReclassifiedWhy we changed it
Registry
Rhinitis, Allergic — the first condition term the registry derived for this study.
ClinicalTrials.gg
Rhinitis, Allergic, Seasonal
Why
  1. The study's listed conditions name Rhinitis, Allergic, Seasonal, a narrower term within Rhinitis, Allergic.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Fraunhofer-Institute of Toxicology and Experimental Medicine · Not applicable, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Rhinitis, Allergic, Seasonal with a site in Germany — 1 open to participants now, 2 under way, none of them phase 3. Rhinitis, Allergic, Seasonal · Germany.

Enrollment
33rd of 35
18 · median 70
Started
2022
with 2 others
No phase
11 of 41
none open now
Registered
38th of 41
by date
Lead sponsor
8 of 41
Fraunhofer-Institute of Toxicology and Experimental Medicine

Among the 41 studies in Rhinitis, Allergic, Seasonal with a site in Germany, this one is the 33rd largest by enrollment of the 35 interventional ones that give a count, is one of 3 that started in 2022, is one of 11 with no phase, and was the 38th registered.

Rhinitis, Allergic, Seasonal

404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.

Browse Rhinitis, Allergic, Seasonal studies →

Open to participants now

1 of the 41 studies in Rhinitis, Allergic, Seasonal with a site in Germany is open now. Recruiting first, the newest first:

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 17 Rhinitis, Allergic, Seasonal studies recruiting now, 2 (12%) set no upper age limit and 15 (88%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Rhinitis, Allergic, Seasonal with a site in Germany, or all of them as a file.
02

Study summary

The ragweed Ambrosia artemisiifolia is spreading in northern Europe due to climate change. The pollen are considered highly allergenic and might trigger allergy symptoms at much lower concentrations than e.g. grass or birch pollen. This study aims to determine threshold concentrations for ragweed and birch pollen in patients with seasonal allergic rhinitis. Participants will be exposed in an allergen challenge chamber that was technically modified to maintain very low and stable pollen concentrations for several hours. The study design is adaptive, where the pollen concentrations are escalated or de-escalated based on interim analysis of resulting allergic symptoms.

Read the detailed description

Ambrosia artemisiifolia (hereafter briefly referred to as ragweed) is an anemophilous herb of the Asteraceae family that probably originated in desert areas of the USA. The plant was introduced to Europe through trade and spread as a successful neophyte during the 20th century. Although conditions are not ideal for ragweed in northern and central Europe, when the plant prefers dry, sandy soils, climate change may be a significant contributor to its spread. The pollen is considered highly allergenic, so it is possible that lower pollen concentrations are sufficient to trigger allergy symptoms compared to native grass or birch pollen. Together with its ability to spread invasively and its tolerance to harmful factors, ragweed is therefore considered a health hazard.

Determining threshold concentrations for various aeroallergens has been attempted many times in published literature. In fact, first experiments have been reported since the 1960s. However, obtaining comparable results prove difficult due to a plethora of methods, outcome measures and choices in study population. Basically, threshold concentration could be assessed by target organ specific allergen challenge, field study and allergen chamber challenge - each of which has its own benefits and drawbacks.

To date, allergen challenge chambers have been used primarily for proof-of-concept studies with antiallergic agents. Technically, the chambers are designed to maintain high pollen concentrations, which should induce symptoms in all sensitized subjects, at a constant level for hours in order to be able to determine the maximum possible effect size of the investigated therapeutic intervention. Metering and monitoring of pollen to maintain stable concentrations present technical challenges for deploying pollen concentrations in the double-digit range. Fraunhofer ITEM has successfully established low concentration pollen exposures, so that allergic patients can be titrated to effect. The pollen concentration will be escalated or de-escalated according to a pre-defined algorithm, based on interim data analysis. Eventually, a concentration range for ragweed and birch pollen can be determined that induces allergic symptoms with clinical and statistical significance.

03

Conditions studied

  • Allergic Rhinitis
  • Seasonal Allergic Rhinitis
  • Ragweed Allergy
  • Birch Pollen Allergy

Browse trials for

04

In context

Rhinitis, Allergic, Seasonal Reclassified

404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.

This study's enrollment of 18 is below the median of 131 across 366 interventional studies indexed under Rhinitis, Allergic, Seasonal.

Browse Rhinitis, Allergic, Seasonal studies →

Lead sponsor

Fraunhofer-Institute of Toxicology and Experimental Medicine is the lead sponsor of 38 studies on the registry; 3 are open to participants now.

Compared within Rhinitis, Allergic, Seasonal, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Rhinitis, Allergic. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to give written .
  2. Male and female subjects, aged 18-65 years. Women will be considered for inclusion if they are:

    1. Not pregnant, as confirmed by pregnancy test (see flow chart), and not nursing.
    2. Of non-child bearing potential (i.e. physiologically incapable of becoming pregnant, including any female who is , with documented proof of hysterectomy or tubal ligation, or meets clinical criteria for menopause and has been amenorrhoeic for more than 1 year prior to the screening visit).
    3. Of and using a highly effective during the entire study as described in section 8.2.
  3. between 18 and 35 kg/m2.
  4. History of seasonal allergic rhinitis to ragweed (July to September) or birch pollen (March to May).
  5. Positive skin prick test response (positive wheal diameter reaction of ≥ 3mm) for Ambrosia artemisiifolia or Betula pendula at screening or within 12 months prior to screening visit.
  6. Subject has a serum specific IgE level (≥ 0.7 kU/L) to Ambrosia artemisiifolia or Betula pendula at screening or within the past 12 months (record required).
  7. Normal lung function ( ≥ 80% pred. and FEV1/FVC ≥ LLN) at screening. If subject fails to meet criteria, assessment may be repeated 2 additional times.
  8. TNSS of 0 prior to entering the ACC at all exposures.
  9. Mild to moderate level of rhinitis symptoms in the screening challenge to ragweed or birch, defined as a mean TNSS between 1 to 8 after the 4-hour ACC and a TNSS continuously > 0 after 40 minutes.

Exclusion criteria

Exclusion Criteria:

  1. Any abnormal findings in physical examination, clinical chemistry, hematology, urinalysis, vital signs, lung function or at screening visit , which, in the opinion of the investigator, may either put the subject at risk because of participation in the study or may influence the results of the study, or the subject's ability to participate in the study.
  2. Past or present disease, which as judged by the investigator, may affect the outcome of this study. These diseases include, but are not limited to, cardiovascular disease, , hepatic disease, renal disease, hematological disease, neurological disease, endocrine disease or pulmonary disease (including but not confined to chronic bronchitis, emphysema, tuberculosis, bronchiectasis or cystic fibrosis).
  3. Subjects with concomitant allergies to seasonal aeroallergens (i.e., grass, trees, weeds, rye; defined as IgE ≥ 3.5 kU/L within the last 12 months prior to screening) which are anticipated to be or become active during study participation.
  4. Subjects with a symptomatic concomitant allergy to an animal dander being exposed during study participation.
  5. Subjects with a symptomatic house dust mite allergy.
  6. Symptoms of a respiratory tract infection within 3 days prior to screening. Subjects may be re-screened if they have been asymptomatic for at least 3 days.
  7. Asthma requiring more than Step 1 medication according to GINA guidelines (Global Initiative for Asthma Management and Prevention, 2021). Asthmatic subjects taking ICS plus long-acting bronchodilator as needed according to Step 1 must to be switched to salbutamol as needed during study participation.
  8. Intake of prohibited medication (refer to Section 9.2).
  9. Smokers who are unable to refrain from smoking within 1 hr prior to and during visits.
  10. Anatomical nasal abnormalities, pronounced nasal septum deviation or nasal polyps blocking nasal air flow on examination or recent nasal surgery.
  11. Participation in a clinical trial with a medicinal product or medical device 30 days prior to Visit 1.
  12. History of drug or alcohol abuse in the past 12 months.
  13. Specific Immunotherapy (SIT) against birch or ragweed within 5 years prior to the study.
  14. Risk of non-compliance with study procedures.
  15. Suspected inability to understand the protocol requirements, instructions and study-related restrictions, the nature, scope, and possible consequences of the study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Sequence A: Exposure to no pollen (placebo), then to first pollen concentration

    Participants are first exposed to no pollen, then challenged with the first pollen concentration, and finally all following concentrations.

    Other: Ragweed pollen, birch pollen, clean air (placebo)

  • Experimental
    Sequence B: Exposure to first pollen concentration, then to no pollen (placebo)

    Participants are first challenged with the first pollen concentration, then with no pollen, and finally with all following concentrations.

    Other: Ragweed pollen, birch pollen, clean air (placebo)

Interventions

  • OtherRagweed pollen, birch pollen, clean air (placebo)

    Participants are exposed for 4 hours in the Fraunhofer Allergen Challenge Chamber with varying pollen concentrations of ragweed or birch pollen and once with clean air, serving as a placebo exposure.

07

What researchers measure

Primary outcomes

  1. Threshold concentrations for ragweed and birch pollen

    Changes in mean Total Nasal Symptom Score (TNSS) of 140 to 240 minutes, nasal secretion, and peak nasal inspiratory flow (PNIF) after challenge with ragweed and birch pollen compared to placebo challenge

    Time frame: Day 1, Day 7, Day 14, Day 21, Day 28 (at least 3 exposure visits, maximum 5 exposure visits)

Secondary outcomes

  1. Determining allergenic potency of ragweed compared to birch pollen

    Mean TNSS of 140 to 240 minutes after challenge with ragweed pollen compared to birch pollen

    Time frame: Day 1, Day 7, Day 14, Day 21, Day 28 (at least 3 exposure visits, maximum 5 exposure visits)

  2. Basophil activation under varying pollen concentrations in vitro

    CD63 expression (%) on whole blood basophils after stimulation with increasing concentrations of ragweed or birch pollen compared to negative control

    Time frame: Screening visit

  3. Neutrophil migration under varying pollen concentrations in vitro

    Neutrophil migration (% above basal migration) towards increasing concentrations of ragweed or birch pollen compared to negative control

    Time frame: Screening visit

Other outcomes

  1. Measuring changes in fractioned exhaled nitric oxide before and after allergen challenges

    Changes in nasal fractionated exhaled nitric oxide (FeNO) after challenge with ragweed and birch pollen compared to pre challenge nasal FeNO and placebo challenge

    Time frame: Day 1, Day 7, Day 14, Day 21, Day 28 (at least 3 exposure visits, maximum 5 exposure visits)

  2. Measuring changes in proinflammatory biomarkers before and after allergen challenges

    Changes in inflammatory biomarkers such as histamine, eotaxin, IL-4, IL-5, IL-6, IL-13, TNF-α and MIP-1β after challenge with ragweed and birch pollen compared to pre challenge and placebo measurements from nasal filter papers

    Time frame: Day 1, Day 2; Day 7, Day 8; Day 14, Day 15; Day 21, 22; Day 28, 29 (at least 3 exposure visits, maximum 5 exposure visits)

  3. Measuring changes in proinflammatory cells before and after allergen challenges

    Changes in concentration of eosinophil and neutrophil granulocytes, macrophages, lymphocytes and monocytes after challenge with increasing cumulative exposures to ragweed and birch pollen compared to pre challenge and placebo measurements from nasal lavage

    Time frame: Day 1, Day 2; Day 7, Day 8; Day 14, Day 15; Day 21, 22; Day 28, 29 (at least 3 exposure visits, maximum 5 exposure visits)

  4. Measuring changes in basophil surface antigen expression under varying pollen concentrations in vitro

    CD63 (%) and CD203c (median fluorescence intensity) expression on whole blood basophils after stimulation with increasing concentrations of ragweed or birch major allergens compared to negative control

    Time frame: Screening visit

  5. Measrung neutrophil migration under varying pollen major allergens concentrations in vitro

    Neutrophil migration (% above basal migration) towards increasing concentrations of ragweed or birch major allergens compared to negative control

    Time frame: Screening visit

08

Study locations

1 site
  • Fraunhofer Institute for Toxicology and Experimental Medicine
    Hanover, Lower Saxony 30625, Germany
09

References and documents

Publications

  • Gaudeul M, Giraud T, Kiss L, Shykoff JA. Nuclear and chloroplast microsatellites show multiple introductions in the worldwide invasion history of common ragweed, Ambrosia artemisiifolia. PLoS One. 2011 Mar 10;6(3):e17658. doi: 10.1371/journal.pone.0017658. PubMed 21423697 ↗
  • Buters J, Alberternst B, Nawrath S, Wimmer M, Traidl-Hoffmann C, Starfinger U, Behrendt H, Schmidt-Weber C, Bergmann KC. Ambrosia artemisiifolia (ragweed) in Germany - current presence, allergological relevance and containment procedures. Allergo J Int. 2015;24:108-120. doi: 10.1007/s40629-015-0060-6. Epub 2015 Jul 11. PubMed 27226949 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Dec 2024, 27 months.

Of 22 interventional studies with no phase under Rhinitis, Allergic, Seasonal, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 22. This study's 27 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2022
First posted
Apr 26, 2022
StartActual
Sep 1, 2022
Primary completionActual
Dec 6, 2024
CompletionActual
Dec 6, 2024
Last update
Jul 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05346718
Lead sponsor
Fraunhofer-Institute of Toxicology and Experimental Medicine
Responsible party
Prof. Dr. Jens Hohlfeld, MD (Division Director of Airway Research, Fraunhofer-Institute of Toxicology and Experimental Medicine) — Principal investigator
First posted
Apr 26, 2022
Start date
Sep 1, 2022
Primary completion
Dec 6, 2024
Completion
Dec 6, 2024
Last update
Jul 24, 2026

Study contacts

Jens M Hohlfeld, Prof. Dr.
principal investigator · Fraunhofer Institute for Toxicology and Experimental Medicine ITEM

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion